{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T10:23:47Z","timestamp":1793528627910,"version":"4.5.0"},"reference-count":39,"publisher":"The Journal of Rheumatology","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>Patients with myositis-associated interstitial lung disease (MA-ILD) are often refractory to conventional treatment, and predicting their response to therapy is challenging. Recent case reports and small series suggest that tacrolimus may be useful in refractory cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>A retrospective cohort study of patients with MA-ILD comparing clinical characteristics between those who responded to or failed conventional treatment. In those who failed conventional treatment and received adjunctive tacrolimus, response to tacrolimus was measured by the improvement in myositis, ILD, and change in the dose of glucocorticoids.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Thirty-one of 54 patients (57%) responded to conventional treatment based on the predefined variables of improvement in myositis and\/or ILD. Patients with polymyositis (PM)-ILD were more likely to respond to conventional treatment than those with dermatomyositis (DM)-ILD (67% vs 35%, p = 0.013). Twenty-three patients failed conventional treatment, 18 of whom subsequently received adjunctive tacrolimus. Ninety-four percent had improvements in ILD and 72% showed improvement in both myositis and ILD. The mean doses of prednisone decreased from baseline by 65% at 3\u20136 months (p = 0.002) and 81% at 1 year (p &lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Patients with PM-ILD were more likely to respond to conventional treatment than patients with DM-ILD, but clinical characteristics and serology did not otherwise predict response to therapy. A majority of patients with MA-ILD refractory to conventional therapy improved while receiving tacrolimus and were able to decrease their dose of both glucocorticoids and other disease-modifying antirheumatic drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.161217","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T20:20:38Z","timestamp":1504297238000},"page":"1612-1618","source":"Crossref","is-referenced-by-count":53,"title":["Myositis-associated Interstitial Lung Disease: Predictors of Failure of Conventional Treatment and Response to Tacrolimus in a US Cohort"],"prefix":"10.3899","volume":"44","author":[{"given":"Niharika","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Putman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rekha","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Strek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha","family":"Dua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2017,9,1]]},"reference":[{"key":"2018112909373341000_44.11.1612.1","doi-asserted-by":"publisher","DOI":"10.1590\/S1806-37132011000100015"},{"key":"2018112909373341000_44.11.1612.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1956.02960520029008b"},{"key":"2018112909373341000_44.11.1612.3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098824"},{"key":"2018112909373341000_44.11.1612.4","doi-asserted-by":"publisher","DOI":"10.1002\/art.23571"},{"key":"2018112909373341000_44.11.1612.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.10794"},{"key":"2018112909373341000_44.11.1612.6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung"},{"key":"2018112909373341000_44.11.1612.7","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-1164-z"},{"key":"2018112909373341000_44.11.1612.8","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.7.2103110"},{"key":"2018112909373341000_44.11.1612.9","doi-asserted-by":"publisher","DOI":"10.1080\/08916930500124023"},{"key":"2018112909373341000_44.11.1612.10","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e328358ac72"},{"key":"2018112909373341000_44.11.1612.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121043"},{"key":"2018112909373341000_44.11.1612.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.02.015"},{"key":"2018112909373341000_44.11.1612.13","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0246-6"},{"key":"2018112909373341000_44.11.1612.14","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20212"},{"key":"2018112909373341000_44.11.1612.15","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121026"},{"key":"2018112909373341000_44.11.1612.16","first-page":"436","article-title":"Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease","volume":"31","author":"Labirua-Iturburu","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909373341000_44.11.1612.17","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s10067-015-3065-0","article-title":"The efficacy of tacrolimus in patients with refractory dermatomyositis\/polymyositis: a systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin Rheumatol"},{"key":"2018112909373341000_44.11.1612.18","first-page":"121","article-title":"[Effectiveness of tacrolimus in a case of polymyositis]","volume":"45","author":"Joki","year":"2005","journal-title":"Rinsho Shinkeigaku"},{"key":"2018112909373341000_44.11.1612.19","first-page":"707","article-title":"Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"23","author":"Ochi","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909373341000_44.11.1612.20","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","article-title":"Tacrolimus in refractory polymyositis with interstitial lung disease","volume":"353","author":"Oddis","year":"1999","journal-title":"Lancet Lond Engl"},{"key":"2018112909373341000_44.11.1612.21","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00014707"},{"key":"2018112909373341000_44.11.1612.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-009-1358-x"},{"key":"2018112909373341000_44.11.1612.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev192"},{"key":"2018112909373341000_44.11.1612.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.21240"},{"key":"2018112909373341000_44.11.1612.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"2018112909373341000_44.11.1612.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807"},{"key":"2018112909373341000_44.11.1612.27","doi-asserted-by":"publisher","DOI":"10.1097\/00002281-199911000-00006"},{"key":"2018112909373341000_44.11.1612.28","first-page":"128","article-title":"The importance of including amyopathic dermatomyositis in the idiopathic inflammatory myositis spectrum","volume":"31","author":"Ghazi","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909373341000_44.11.1612.29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2018112909373341000_44.11.1612.30","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.ats3-00"},{"key":"2018112909373341000_44.11.1612.31","first-page":"58","article-title":"Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis","volume":"32","author":"Fujisawa","year":"2005","journal-title":"J Rheumatol"},{"key":"2018112909373341000_44.11.1612.32","doi-asserted-by":"publisher","DOI":"10.1080\/08916930600622132"},{"key":"2018112909373341000_44.11.1612.33","doi-asserted-by":"publisher","DOI":"10.1080\/08916930600623791"},{"key":"2018112909373341000_44.11.1612.34","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3181b0e910"},{"key":"2018112909373341000_44.11.1612.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61079-4"},{"key":"2018112909373341000_44.11.1612.36","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.49.2889"},{"key":"2018112909373341000_44.11.1612.37","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4103\/0971-3026.125570","article-title":"Significance of various pulmonary and extrapulmonary abnormalities on HRCT of the chest in scleroderma lung","volume":"23","author":"Pandey","year":"2013","journal-title":"Indian J Radiol Imaging"},{"key":"2018112909373341000_44.11.1612.38","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s11547-015-0526-0","article-title":"Idiopathic interstitial pneumonias: do HRCT criteria established by ATS\/ERS\/JRS\/ALAT in 2011 predict disease progression and prognosis?","volume":"120","author":"Romei","year":"2015","journal-title":"Radiol Med"},{"key":"2018112909373341000_44.11.1612.39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/1471-2474-13-228","article-title":"Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis\/dermatomyositis: a retrospective study","volume":"13","author":"Shimojima","year":"2012","journal-title":"BMC Musculoskelet Disord"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.161217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T14:22:57Z","timestamp":1543501377000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.161217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,1]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11,1]]},"published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.3899\/jrheum.161217"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.161217","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,1]]}}}